NCT06718998View on ClinicalTrials.gov

A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or Obesity

PHASE1RecruitingINTERVENTIONAL

Enrollment

114

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

January 8, 2026

Study Completion Date

January 8, 2026

Conditions

Obesity

Interventions

DRUG

NNC0519-0130

Participants will receive once-weekly or twice weekly NNC0519-0130 subcutaneously.

Trial Locations (1)

8010

RECRUITING

Medical University of Graz, Graz

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY